CareDx, Inc (NASDAQ:CDNA) Holdings Cut by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC reduced its position in CareDx, Inc (NASDAQ:CDNA - Free Report) by 37.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 70,551 shares of the company's stock after selling 41,385 shares during the quarter. Los Angeles Capital Management LLC owned about 0.13% of CareDx worth $2,203,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in CDNA. Allspring Global Investments Holdings LLC raised its position in shares of CareDx by 10,267.2% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 18,661 shares of the company's stock worth $198,000 after buying an additional 18,481 shares during the period. Janney Montgomery Scott LLC purchased a new position in shares of CareDx in the 1st quarter worth $238,000. Russell Investments Group Ltd. increased its holdings in CareDx by 35.0% in the 1st quarter. Russell Investments Group Ltd. now owns 122,227 shares of the company's stock valued at $1,294,000 after purchasing an additional 31,667 shares in the last quarter. Vanguard Group Inc. increased its holdings in CareDx by 4.4% in the 1st quarter. Vanguard Group Inc. now owns 4,300,016 shares of the company's stock valued at $45,537,000 after purchasing an additional 180,334 shares in the last quarter. Finally, Acadian Asset Management LLC increased its holdings in CareDx by 4.7% in the 1st quarter. Acadian Asset Management LLC now owns 869,518 shares of the company's stock valued at $9,206,000 after purchasing an additional 38,888 shares in the last quarter.

CareDx Stock Down 5.6 %

Shares of CareDx stock traded down $1.27 during trading hours on Thursday, hitting $21.51. 66,014 shares of the company's stock traded hands, compared to its average volume of 898,479. The stock has a 50 day simple moving average of $26.91 and a 200-day simple moving average of $21.52. The company has a market cap of $1.15 billion, a PE ratio of -8.44 and a beta of 1.80. CareDx, Inc has a twelve month low of $7.42 and a twelve month high of $34.84.

CareDx (NASDAQ:CDNA - Get Free Report) last announced its earnings results on Monday, November 4th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.11. The company had revenue of $82.88 million during the quarter, compared to the consensus estimate of $80.04 million. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The company's revenue was up 23.4% on a year-over-year basis. During the same period last year, the firm earned ($0.43) earnings per share. As a group, equities research analysts predict that CareDx, Inc will post -0.7 EPS for the current year.

Insider Buying and Selling

In related news, insider Alexander L. Johnson sold 21,557 shares of CareDx stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $32.58, for a total value of $702,327.06. Following the completion of the transaction, the insider now directly owns 284,983 shares in the company, valued at approximately $9,284,746.14. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other CareDx news, insider Alexander L. Johnson sold 34,231 shares of the firm's stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $33.55, for a total value of $1,148,450.05. Following the transaction, the insider now owns 284,983 shares of the company's stock, valued at $9,561,179.65. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Alexander L. Johnson sold 21,557 shares of the firm's stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $32.58, for a total transaction of $702,327.06. Following the completion of the transaction, the insider now directly owns 284,983 shares in the company, valued at $9,284,746.14. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 91,340 shares of company stock worth $3,025,415. Corporate insiders own 4.90% of the company's stock.

Analyst Ratings Changes

CDNA has been the subject of several recent research reports. Wells Fargo & Company initiated coverage on CareDx in a report on Tuesday, August 27th. They issued an "underweight" rating and a $28.00 price target for the company. BTIG Research lowered their price target on CareDx from $40.00 to $35.00 and set a "buy" rating for the company in a report on Tuesday, November 5th. StockNews.com upgraded CareDx from a "hold" rating to a "buy" rating in a report on Thursday, October 17th. HC Wainwright reiterated a "neutral" rating on shares of CareDx in a report on Tuesday, October 22nd. Finally, The Goldman Sachs Group increased their price target on CareDx from $26.00 to $35.00 and gave the company a "buy" rating in a report on Wednesday, October 16th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. According to MarketBeat, CareDx has a consensus rating of "Moderate Buy" and a consensus target price of $29.60.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.